浙江东方基因生物制品股份有限公司 投资理财管理制度 浙江东方基因生物制品股份有限公司 投资理财管理制度 第一章 总 则 第一条 为规范浙江东方基因生物制品股份有限公司（以下简称"公司"） 投资理财业务的管理，提高资金运作效率，保证公司资金、财产安全，有效防范 投资风险，维护股东和公司的合法权益，根据《上海证券交易所科创板股票上市规 则》等法律法规及《公司章程》的有关规定，结合公司实际情况，制定本制度。 第二条 本制度所指"投资理财管理"是指在国家政策及科创板相关业务规 则允许的情况下，公司在控制投资风险的前提下，以提高资金使用效率、增加 公司收益为原则，对闲置资金通过商业银行理财、信托理财及其他理财工具进 行运作和管理，在确保安全性、流动性的基础上实现资金保值增值的行为。 第二章 管理原则 第三条 本制度适用于公司及控股子公司。公司控股子公司进行投资理财须 报经公司审批，未经审批不得进行任何投资理财活动。 第四条 公司投资理财管理应遵守如下原则： （一）公司投资理财业务应坚持"规范运作、防范风险、谨慎投资、保值 增值"的原则，以不影响公司正常经营和主营业务的发展为先决条件。 1 浙江东方基因生物制品股份有限公 ...

浙江东方基因生物制品股份有限公司 董事会秘书工作细则 第二章 董事会秘书的任职资格 第三条 董事会秘书应当具备履行职责所必需的工作经验和财务、管理、法 律等专业知识，具有良好的职业道德和个人品质，并取得证券交易所认可的董事 会秘书资格证书。具有下列情形之一的人士不得担任董事会秘书： （一）有《公司法》第一百七十八条规定情形之一的； （二）最近 3 年曾受中国证监会行政处罚，或者被中国证监会采取市场禁入 措施，期限尚未届满； 浙江东方基因生物制品股份有限公司 董事会秘书工作细则 第一章 总则 第一条 为了促进浙江东方基因生物制品股份有限公司（以下简称"公司" 或"本公司"）的规范运作，规范董事会秘书的行为，加强对董事会秘书工作的 指导，充分发挥董事会秘书的作用，根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《股 票上市规则》"）以及《浙江东方基因生物制品股份有限公司章程》（以下简称 "《公司章程》"），特制订本工作制度。 第二条 公司设立董事会秘书一名。董事会秘书为公司高级管理人员，对公 司和董事会负责。法律、法规及《公司章程》对公司高级管理人员的有关 ...

浙江东方基因生物制品股份有限公司 股东会议事规则 浙江东方基因生物制品股份有限公司 股东会议事规则 第一章 总 则 第一条 为规范浙江东方基因生物制品股份有限公司（以下简称"公司"） 行为，保证股东会依法行使职权，根据《公司法》《证券法》《上市公司治理准则》 《上市公司股东会规则》《上海证券交易所科创板股票上市规则》（以下简称"《股 票上市规则》"）、《上市公司章程指引》以及《公司章程》等有关规定，特制定本 议事规则。 第二条 股东会是公司的权力机构，应当在《公司法》和公司章程规定的 范围内行使职权。 第三条 公司应当严格按照法律、行政法规、公司章程及本规则的相关规 定召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第二章 股 东 第四条 公司股东为依法持有公司股份的人。 股东按其所持有股份的类别享有权利，承担义务；持有同一类别股份的股东， 享有同等权利，承担同种义务。 第五条 股东名册是证明股东持有公司股份的充分证据。 第六条 公司依据证券登记结算机构提供的凭证建立股东名册。 第七条 公司召开股东会、分 ...

Group 1 - The animal vaccine sector experienced a decline of 0.72% as of the market close on August 22, ranking among the top declines in concept sectors [1] - Within the animal vaccine sector, companies such as Shenlian Biological, Weilan Biological, and Xianfeng Holdings saw significant declines, while Kexing Pharmaceutical, Haizheng Pharmaceutical, and Guoyao Modern recorded increases of 2.06%, 0.44%, and 0.09% respectively [1] - The overall market saw a net outflow of 0.68 billion yuan from the animal vaccine sector, with 11 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 10 million yuan [2] Group 2 - The top net outflow in the animal vaccine sector was from Kanghua Biological, with a net outflow of 30.50 million yuan, followed by Shenlian Biological, Dabeinong, and Jinhai Biological with outflows of 27.38 million yuan, 24.27 million yuan, and 23.53 million yuan respectively [2] - Conversely, the stocks with the highest net inflows included Haizheng Pharmaceutical, Kexing Pharmaceutical, and Luoniushan, with net inflows of 27.34 million yuan, 16.70 million yuan, and 10.38 million yuan respectively [3] - The trading activity in the animal vaccine sector showed that Kanghua Biological had a turnover rate of 3.52% and a decline of 1.70%, while Kexing Pharmaceutical had a turnover rate of 3.12% and an increase of 2.06% [3]

Policy Developments - The National Medical Insurance Administration held a mid-year meeting in Xi'an, focusing on enhancing the development of medical institutions and the pharmaceutical industry, ensuring public health, and improving the basic medical insurance system [2] Drug and Device Approvals - Heng Rui Medicine's application for the marketing license of Haequibopamine tablets has been accepted by the National Medical Products Administration, aimed at treating chemotherapy-induced thrombocytopenia in adult patients [4] - Dongfang Bio and its subsidiaries have obtained multiple medical device registration certificates, including flu virus antigen test kits and other diagnostic tools, enhancing the company's product range and market competitiveness [5] - Zhifei Biological's clinical trial application for a component DTP vaccine for adolescents and adults has been accepted, with significant market potential as no similar vaccine is currently approved for this demographic [6] Financial Reports - Fuyuan Medicine reported a 1.30% decrease in revenue to 1.634 billion yuan and a 7.83% decline in net profit to 268 million yuan for the first half of 2025 [8] - Jiuyuan Gene achieved total revenue of 638.8 million yuan and a net profit of 90.2 million yuan, with over 10% growth in orthopedic product sales despite industry challenges [9] - Kangzhe Pharmaceutical reported a 10.8% increase in revenue to approximately 4 billion yuan and a 3.1% rise in net profit to about 930 million yuan for the first half of 2025 [11] Capital Market - Kening Bio completed a multi-million A-round financing to support clinical research for its core pipelines targeting osteoarthritis and dry eye syndrome, with plans to start overseas clinical trials in 2026 [13] Industry Events - A new decision-making framework called FRAME was proposed by a research team from the Chinese Academy of Sciences, showing significant improvements in medical insights using large language models [15] - Ant Group launched initiatives to combat fake medical advertisements through its AI health application, aiming to protect public interests amid increasing regulatory scrutiny [16] Shareholder Actions - Guoshou Chengda has reduced its stake in Maipu Medical by 2.9958%, completing its share reduction plan [18] - Sichuang Medical's vice president resigned for personal career planning reasons, indicating potential changes in company leadership [19]

Policy Developments - The National Medical Insurance Work Mid-Year Symposium was held in Xi'an, Shaanxi, on August 15, 2025, focusing on the progress and future priorities of medical insurance work, emphasizing the need for empowerment of medical institutions and innovation in the pharmaceutical industry [1] Drug and Device Approvals - Heng Rui Medicine announced that its application for the marketing authorization of Haqubopam Ethanolamine Tablets has been accepted by the National Medical Products Administration, aimed at treating chemotherapy-induced thrombocytopenia in adult patients [2] - Dongfang Bio reported that it and its subsidiaries obtained multiple medical device registration certificates, including flu virus antigen test kits and various antibody test kits, enhancing its product range and market competitiveness [3] - Zhifei Biological's clinical trial application for a component DTP vaccine for adolescents and adults has been accepted, with significant market potential as no similar vaccine is currently approved for this demographic in China [4] Financial Reports - Fuyuan Medicine reported a 1.30% decrease in revenue to 1.634 billion yuan and a 7.83% decline in net profit to 268 million yuan for the first half of 2025 [5] - Jiuyuan Gene announced total revenue of 638.8 million yuan and a net profit of 90.2 million yuan, facing challenges from policy changes and internal adjustments, but showing resilience with over 10% growth in orthopedic product sales [6] - Kangzhe Pharmaceutical reported a 10.8% increase in revenue to approximately 4 billion yuan and a 3.1% rise in net profit to about 930 million yuan for the first half of 2025 [7] Capital Market - Kegong Bio completed a multi-million A-round financing, which will support its clinical research for core pipelines targeting osteoarthritis and dry eye syndrome, with plans to start overseas clinical trials in 2026 [8] Industry Developments - A new decision-making framework for medical large models, FRAME, was proposed by a research team from the Chinese Academy of Sciences, showing significant improvements in medical insights compared to traditional methods [9] - Ant Group has launched initiatives to combat fake medical advertisements through its AI health application, AQ, which includes features for users to verify medical claims [10] Shareholder Actions - Guoshou Chengda has completed a reduction of 2.9958% of its shares in Maipu Medical, reducing its holdings to 1.9093% of the total share capital [11] - Sichuan Medical's Vice President resigned for personal career planning reasons, stepping down from all positions within the company [12]

证券代码：688298 证券简称：东方生物 公告编号：2025-038 ■ 二、境外医疗器械注册证基本情况如下： ■ 三、对上市公司的影响 公司甲型/乙型流感病毒抗原检测试剂的取证，进一步丰富了公司在国内呼吸道联检领域的可销售产品 种类，有利于应对常规季节性呼吸道感染的检测；抗髓过氧化物酶抗体、抗蛋白酶3抗体、抗肾小球基 底膜抗体检测试剂的获证，丰富了流式荧光（原液态生物芯片）技术平台的配套检测试剂品种，扩展了 流式荧光发光法的应用领域，有利于国内市场的整体拓展。 浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"东方生物"或"公司"）及全资子公司Healgen Scientific LLC（以下简称"美国衡健"）、上海万子健生物技术有限公司（以下简称"上海万子健生物"）近日取得 了以下几款医疗器械注册证书，内容公告如下： 一、境内医疗器械注册证基本情况如下： 四、风险提示 上述产品的实际销售业绩取决于产品的 ...

Group 1 - The company Dongfang Biological announced on August 18 that Zhejiang Dongfang Gene Biological Products Co., Ltd. and its wholly-owned subsidiary Healgen Scientific LLC, along with Shanghai Wanzijian Biotechnology Co., Ltd., have recently obtained several medical device registration certificates [2] - The registered products include the "A/H1N1 and B Influenza Virus Antigen Detection Kit (Colloidal Gold Method) (Professional)" among others [2]

证券代码：688298 证券简称：东方生物 公告编号：2025-038 浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"东方生物"或"公司"） 及全资子公司Healgen Scientific LLC（以下简称"美国衡健"）、上海万子健 生物技术有限公司（以下简称"上海万子健生物"）近日取得了以下几款医疗器 械注册证书，内容公告如下： 一、境内医疗器械注册证基本情况如下： 浙江东方基因生物制品股份有限公司 上述产品的实际销售业绩取决于产品的实际竞争力和市场销售能力，目前尚 无法预测对公司未来经营业绩的影响，敬请投资者注意投资风险。 特此公告。 | 产品名称 | 适用国家及证 书编号 | 证书类型 | 预期用途 | 有效期 | 持证 公司 | | --- | --- | --- | --- | --- | --- | | | | | 本产品用于体外定性检测人鼻拭 | 2025/8/14 | | | 甲型/乙型流 ...

东方生物(688298.SH)公告，公司及全资子公司美国衡健、上海万子健生物近日取得了以下几款医疗器 械注册证书，产品名称为：甲型/乙型流感病毒抗原检测试剂盒(胶体金法)(专业)、抗髓过氧化物酶抗 体、抗蛋白酶3抗体、抗肾小球基底膜抗体检测试剂盒(流式荧光发光法)、Healgen Immunofluorescence Analyzer(OG-H180)衡健荧光免疫分析仪(OG-H180)、Healgen AccuFluor Fentanyl Fluorescence Immunoassay(FIA)Test Kit-Qualitative衡健芬太尼荧光免疫层析检测试剂。 ...